REQUIP® (Ropinirole)

GlaxoSmithKleine

REQUIP ® information courtesy of GlaxoSmithKleine

Last updated March 2007

This section provides a summary of the drug information for REQUIP® (Ropinirole). It is still important that you read the full package leaflet that accompanies the product carefully before you start to take any medication. If you have any further questions about your PD medication, or other aspects of your PD treatment, you should discuss these with your doctor or other healthcare professional.

  • Requip® Starter Pack
  • Requip® Follow On Pack

Click on images to enlarge

Parkinson’s disease is caused by a substance called dopamine in the brain dropping to low levels. REQUIP® belongs to a group of medicines known as dopamine agonists and it acts in a similar way to the natural dopamine, so helping the symptoms of Parkinson’s disease.

Top of page

REQUIP® Availability

REQUIP® (Ropinirole) is currently available in the following countries:

    Worldwide Availability
  • Argentina
  • Aruba
  • Australia
  • Austria
  • Bahrain
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Cyprus *
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Iceland
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Kuwait **
  • Latvia
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malaysia
  • Malta
  • Moldova
  • Morocco
  • Netherlands
  • Netherlands Antilles
  • New Zealand
  • Norway
  • Oman*
  • Pakistan
  • Peru
  • Philippines*
  • Poland
  • Portugal
  • Romania
  • Saudi Arabia
  • Singapore
  • Slovak Republic
  • Slovenia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • Trinidad & Tobago *
  • Tunisia
  • Turkey
  • UAE
  • UK
  • Ukraine
  • USA
  • Venezuela

* ™ Trade mark pending
** Unregistered trade mark

Please note REQUIP® is also approved in Yugoslavia (Serbia) but not marketed there.

Top of page

Availability - Formulation

REQUIP® (ropinirole) tablets come in the following strengths:

  • REQUIP® Tablets 0.25 mg
  • REQUIP® Tablets 0.5 mg
  • REQUIP® Tablets 1 mg
  • REQUIP® Tablets 2 mg
  • REQUIP® Tablets 5 mg
Top of page

Product Information Downloads

The information on this pageprintout is a general summary of the REQUIP® medication product.

Please click on the links below to download more detailed information on the specific REQUIP® medication, its handling and use. Links go to the electronic Medicines Compendium (eMC) website.

Further detailed information on the specific REQUIP® medication, its handling and use can be downloaded via the electronic Medicines Compendium (eMC) website (http://emc.medicines.org.uk/):

UK Patient Information Leaflets (PIL)

UK Summary of Product Characteristics (SPC)

Please note that SPCs are designed for healthcare professionals.

Top of page

Useful Links & References

REQUIP® is a registered trade mark of the GlaxoSmithKline group of companies. REQUIP® is an unregistered trade mark of the GlaxoSmithKline group of companies in Cyprus (application pending), Kuwait, Oman (application pending), Philippines, Trinidad and Tobago.

Top of page

Further Information

GlaxoSmithKline UK
Stockley Park West
Uxbridge
Middlesex
UB11 1BT
United Kingdom

Freephone: 0800 221441
Fax: 020 8990 4328
Email: customer contactuk@gsk.com